Condition Focus: Fibromyalgia — Gold-Standard Triple-Blinded Pain Trial
In clinical research, “triple-blinded” represents the highest standard of bias control: the patients do not know which treatment they received, the clinicians administering the treatment do not know, and the researchers analysing the data do not know. This 2022 RCT from Navarro-Ledesma and colleagues achieved this gold standard while demonstrating that whole-body PBM produces statistically significant pain reduction in fibromyalgia patients.
The study used a NovoTHOR whole-body PBM pod delivering red and near-infrared wavelengths simultaneously across the entire body surface. The pain reduction was not only statistically significant during the treatment period but was maintained at the 2-week follow-up assessment — demonstrating that PBM’s effects are not merely transient but persist beyond the treatment window.
While fibromyalgia and gout are different conditions, the trial design is what matters here. Triple-blinded methodology eliminates the three most common objections to PBM evidence: “patients feel better because they expect to” (patient blinding), “clinicians treat differently when they know” (clinician blinding), and “researchers find what they’re looking for” (analyst blinding). When PBM produces significant results through all three layers of blinding, the effect is real.
The systemic pain modulation demonstrated with whole-body treatment also supports the concept that PBM acts through genuine biological mechanisms (mitochondrial, anti-inflammatory, neural) rather than local thermal or placebo effects.
G.O.A.T. for Gout Alignment:
While the G.O.A.T. delivers localised rather than whole-body PBM, the gold-standard trial design demonstrated here validates PBM’s pain-modulating mechanism. The sustained effect at 2-week follow-up supports the G.O.A.T.’s maintenance dosing protocol for chronic gout management.
Link to original research here
Editor’s note: This triple-blind design provides the strongest bias control in PBM pain research. For the localised joint pain evidence, see the knee OA meta-analysis by Oliveira et al 2024. The cytokine-confirmed pain mechanism is demonstrated in PBM Efficacy for Pain and Inflammation 2023. For the musculoskeletal pain meta-analysis across multiple conditions, see Clijsen et al 2017.
Related Articles
- PBM for Knee OA Pain and Disability: Meta-Analysis – Oliveira et al 2024
- Efficacy of PBM in Treatment of Pain and Inflammation – 2023
- Effects of LLLT on Pain in Musculoskeletal Disorders: Meta-Analysis – Clijsen et al 2017
- PBM on Pain and Return to Play of Injured Athletes – Morgan et al 2024
- Effects of PBM on Multiple Health Outcomes: Umbrella Review – Son et al 2025
Key Takeaways
- Triple-blinded RCT — the highest standard of clinical trial bias control
- Significant pain reduction maintained at 2-week follow-up — not just transient
- Triple blinding eliminates patient expectation, clinician, and analyst bias
- Whole-body treatment confirms systemic biological mechanism, not local placebo
Study Overview
| Study Type: | Triple-blinded randomised controlled trial |
| Wavelength(s): | Red + NIR (NovoTHOR whole-body system) |
| Treatment Protocol: | Whole-body PBM sessions with follow-up at 2 weeks |
| Sample Size: | RCT with fibromyalgia patients |
| Primary Outcome: | Significant pain reduction maintained at 2-week follow-up |
Full Citation
Navarro-Ledesma S, et al. (2022). Short-term effects of whole-body photobiomodulation on pain, quality of life, and psychological factors in a population suffering from fibromyalgia: a triple-blinded randomised clinical trial. Pain and Therapy, 12, 225–239. View Publication
